Non-high-density lipoprotein cholesterol may predict the cardio-cerebrovascular risk in patients on maintenance hemodialysis

• Published in: Lipids in health and disease Vol. 20; no. 1; pp. 159 - 8
• Main Authors: Luo, Denggui, Luo, Yueming, Zou, Yanhong, Xu, Yuanzhao, Fu, Bo, Yang, Dong, Yang, Jun, Xu, Cai, Ling, Shuyi, Li, Shunmin, Qi, Airong
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 13.11.2021; BioMed Central; BMC
• Subjects: Ability tests; Adult; Age; Aged; Anticoagulants; Blood; Blood platelets; Body mass index; Cardio-cerebrovascular risk; Cardiovascular disease; Cardiovascular diseases; Cardiovascular Diseases - etiology; Cardiovascular Diseases - mortality; Care and treatment; Cerebrovascular disease; Cerebrovascular diseases; Cerebrovascular Disorders - etiology; Cerebrovascular Disorders - mortality; Cholesterol; Cholesterol, HDL - blood; Cholesterol, LDL; Cholesterol, LDL - blood; Chronic kidney failure; Creatinine; Female; Health aspects; Hemodialysis; Hemodialysis patients; Hemoglobin; High density lipoprotein; Humans; Kaplan-Meier Estimate; Laboratories; Lipids; Lipoproteins; Maintenance hemodialysis; Male; Measurement; Middle Aged; Mortality; Non-LDL-C; Patients; Prognosis; Proteins; Renal Dialysis - adverse effects; Renal Dialysis - mortality; Retrospective Studies; Risk Factors; Software; Triglycerides; Triglycerides - blood; Uric acid; China; Maintenance hemodialysis; Non-LDL-C; Cardio-cerebrovascular risk
• ISSN: 1476-511X; 1476-511X
• DOI: 10.1186/s12944-021-01546-1

Non-high-density lipoprotein cholesterol (non-HDL-C) may be an independent risk factor for cardio-cerebrovascular disease (CVD); however, the cutoff level in patients on maintenance hemodialysis (MHD) is unknown. This was a retrospective multicenter study of MHD patients treated at 10 dialysis centers in Guangdong Province from July 1, 2016, to April 1, 2017. Laboratory test data were collected and CVD complications and outcomes recorded. In total, 1288 eligible patients were included in this study; the non-HDL-C interquartile range was 2.76 (2.24-3.45) mmol/L. Over a median follow-up time of 24 months, 141 patients developed CVD. The non-HDL-C level was a principal risk factor for such events (P < 0.05; 95% confidence interval 0.800-0.842). The maximum Youden index was 0.549 and the best cutoff > 3.39 mmol/L. Higher baseline non-HDL-C levels may increase the CVD risk in MHD patients. Thus, non-HDL-C effectively predicts CVD.